Bruker Corporation Appoints William J. Knight to Chief Operating Officer and Brian P. Monahan to Chief Financial Officer

Corporation Appoints William J. Knight to Chief Operating Officer and Brian P.

Monahan to Chief Financial Officer

Mass. November 9, 2009 (BUSINESS WIRE)

Bruker Corporation (NASDAQ:

BRKR) today announced that its Board of Directors has appointed Bill Knight to

Chief Operating Officer (COO) and Brian Monahan to Chief Financial Officer

(CFO), with an effective date of February 1st, 2010.

Presently, Bill Knight is serving as CFO, and Brian Monahan is serving

as Chief Accounting Officer of Bruker Corporation.

Laukien, Bruker s President and CEO, stated: Bruker has a 49 year proud

history of technology leadership and customer-focused product innovation. Going forward, we believe that the

combination of continued innovation and an increased focus on operational

excellence will drive margin expansion, balance sheet metrics and cash flow for

increasing shareholder value. In order

to drive our operational excellence initiative, we have created the new

position of Chief Operating Officer at Bruker Corporation.

continued: Today, we are very pleased to announce the promotion of two

extremely capable individuals to expanded responsibilities. Over the past five years, Bill Knight has

demonstrated strong financial and operational leadership at Bruker, and in his

newly-created COO role Bill will lead and fully focus on our operation

excellence initiative. Brian Monahan has

been a key leader and contributor in our finance organization over the past

five years, and we believe he is an excellent choice to succeed Bill as our

Bruker Corporation as CFO and Treasurer in October 2004. At Bruker, Mr. Knight is also the

President of the Bruker Detection business in the United States. Before joining the Company, Mr. Knight

served as an operations-focused CFO in several public companies, and was a

founder of ATI Technologies, an analytical instruments company, where he had

both financial and operational responsibilities. Mr. Knight served as CFO of Anika

Therapeutics, Inc., from 2002 to 2004.

He served as CFO of Zycos, Inc., a developer of DNA-based

therapeutic products, from 2000 to 2002, and as CFO of NMT Medical, Inc.,

a provider of cardiovascular and neurological medical devices, from 1998 to

2000. Mr. Knight is a Certified

Public Accountant and holds a B.B.A. in Accounting from the University of

Bruker Corporation as the Corporate Controller in April 2004 and was

appointed Chief Accounting Officer and Vice President of Finance in March 2009.

In addition to his corporate responsibilities, Mr. Monahan has served in

both financial and operational roles in the Bruker Daltonics division, where he

has been an Executive Vice President of Bruker Daltonics since November 2006

and General Manager of the Americas since July 2008. From January 2005 to November 2006,

Mr. Monahan was Vice President of Finance for Bruker Daltonics, and from July 2004

to January 2005 he was Assistant Vice President of Finance for Bruker Daltonics. Before joining the Company, from 2002 through

2004, Mr. Monahan served as the Manager of Accounting and Financial

Reporting at Fisher Scientific International, Inc., and as an audit

PricewaterhouseCoopers LLP from 1999 through 2002. Mr. Monahan is a Certified Public

Accountant and holds a B.S. in Accounting from the University of Massachusetts.

Bruker Corporation is a leading provider of

high-performance scientific instruments and solutions for molecular and

materials research, as well as for industrial and applied analysis. For more

information about Bruker Corporation, please visit www.bruker.com.

statements contained in this press release that do not describe historical

facts may constitute forward-looking statements as that term is defined in the

Private Securities Litigation Reform Act of 1995. Any forward-looking

statements contained herein are based on current expectations, but are subject

to risks and uncertainties, that could cause actual future results to differ

materially from those projected including, but are not limited to, risks and

uncertainties relating to adverse changes in conditions in the global economy

and volatility in the capital markets, the integration of businesses we have

acquired or may acquire in the future, changing technologies, product

development and market acceptance of our products, the cost and pricing of our

products, manufacturing, competition, dependence on collaborative partners and

key suppliers, capital spending and government funding policies, changes in

governmental regulations, realization of anticipated benefits from economic

stimulus programs, intellectual property rights, litigation, and exposure to

foreign currency fluctuations and other risk factors discussed from time to

time in our filings with the Securities and Exchange Commission. These and

other factors are identified and described in more detail in our filings with

the SEC, including, without limitation, our recent Proxy Statements on Schedule

14A, our annual report on Form 10-K for the year ended December 31,

2008, our most recent quarterly reports on Form 10-Q and our current

reports on Form 8-K. We expressly disclaim any intent or obligation to

update these forward-looking statements other than as required by law.

Source: Bruker Corporation